8 results about "Autoimmune Reactions" patented technology

The present invention relates to a composition for preventing or treating autoimmune diseases. In particular the present invention relates to a composition that prevents or treats the disease by specifically targeting the immune cells responsible for the autoimmune reaction. Thus one aspect relates to a composition comprising DDA and TDB or MMG, retinoic acid or analogues thereof, and at least one autoimmune antigen for use in prevention or treatment of autoimmune diseases.

The present disclosure provides, inter alia, molecules comprising an autoantibody binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The invention discloses a drug-induced autoimmune response prediction method based on oversampling and classification modeling. The method comprises the steps that a drug-induced autoimmune response data set is acquired and preprocessed; the SNN-DPC is adopted to cluster the preprocessed data set; according to the JS divergence, selecting and marking clusters with class distribution similar to global distribution, and calculating the number of samples needing to be generated for the marked clusters based on a Kulczynski index and Gaussian density; synthesizing an oversampling sample in the mark cluster through density weighted three-point interpolation; performing LOF noise removal on the synthetic samples and rejecting boundary samples to form a balanced data set; and training and selecting an optimal classifier to construct a prediction model, and outputting a prediction category and probability. According to the method, data distribution is balanced through generated high-quality minority samples, the recognition capability of a classification model on drug-induced autoimmune positive samples is effectively enhanced, the accuracy of drug immunotoxicity prediction is greatly improved, and immunotoxicity evaluation in the drug research and development process can be assisted.

The application discloses a cell membrane modified nanocomposite as well as a preparation method and application thereof. The nanocomposite comprises, from outside to inside, a membrane structure outer layer, a piezoelectric material middle layer and a magnetostrictive material core structure, wherein the outer surface of the membrane structure contains protein molecules. Under the stimulation of an external magnetic field, the nanocomposite can regulate Th1 / Th2 balance, promote Th2 cell polarization and enhance T cell proliferation, thereby reducing T cell-mediated autoimmune reactions and maintaining host immune homeostasis, and has a wide application prospect in the treatment of arthritis.

Provided herein are methods and compositions involving chromene derivatives acting as TCR or TCR-Nck inhibitors, and CAR-T therapies. The provided methods include the use of a chromene derivative in combination with a CAR-T therapy for treating a disease or disorder, for preventing or reducing an autoimmune reaction associated with a CAR-T therapy, and for increasing or improving a CAR-T therapy effectiveness.

The application discloses a use of an active ingredient in repairing heart tissue damage. Specifically, the application discloses an active ingredient which can be used for repairing heart tissue damage and treating diseases related to lymphatic vessel abnormalities, and the active ingredient comprises a TBX1 protein, a coding sequence of the TBX1 protein, or a promoter of the TBX1 protein, or a combination thereof. The TBX1 protein can promote the proliferation of heart lymphatic vessel endothelial cells, play an immune regulation role, promote the establishment of an immune inhibition microenvironment in myocardium after heart tissue damage, inhibit an autoimmune reaction after the heart tissue damage, relieve concurrent heart tissue inflammation, and promote the repair and regeneration of the damaged heart tissue.

The present disclosure provides, inter alia, molecules comprising an autoantibody binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The invention discloses preparation and application of a double-targeting polypeptide drug based on gold nanoparticles, and belongs to the technical field of preparation of leucoderma drugs. MC1R agonist peptide 1 and T96 are coupled to the gold nanoparticles; multiple treatment effects of protecting melanocytes, promoting melanin synthesis and inhibiting autoimmune response can be realized at the same time, and a brand new thought and method are provided for treatment of vitiligo.